Nautilus Biotechnology

Dr. Parag Mallick, a Stanford professor and Nautilus Biotechnology co-founder, envisions a future where proteomics addresses global challenges. His Nautilus platform aims to measure the entire proteome in a single experiment, using innovative techniques like Protein Identification by Short Epitope Mapping (PrISM) and nanofabricated landing pads. Mallick's diverse passions, including circus performance and magic, enrich his scientific approach, emphasizing the importance of individuality in science.

Nautilus Biotechnology's share registry shows insiders hold 32%, with Parag Mallick as Top Key Executive owning 16%. Institutional investors hold a good portion, and the top 4 shareholders control over half the company. The general public holds 13%, while private equity firms have a 30% stake. Private companies own 3.3%, and Nautilus Biotechnology shows 4 warning signs, 2 of which shouldn't be ignored.

Goldman Sachs downgraded Nautilus Biotechnology (NASDAQ:NAUT) from neutral to sell, with a price objective of $1.75. NAUT opened at $2.14, with a market cap of $268.70 million. Nautilus reported a quarterly EPS of ($0.13), beating estimates by $0.04. VP Mary E. Godwin sold 35,000 shares at $2.85 each. Institutional investors like Barclays PLC and Wexford Capital LP increased their stakes, while MetLife Investment Management LLC and The Manufacturers Life Insurance Company acquired new positions. Nautilus Biotechnology focuses on developing a proteomics platform.

Goldman Sachs analyst Matthew Sykes downgraded Nautilus Biotechnology to Sell from Neutral with a $1.75 price target, reflecting a 21% downside. The market for discovery proteomics has become more competitive, with Nautilus’ instrument launch timeline delayed.

Chat with this insight to save time by focusing on the most important pieces.

Goldman Sachs downgraded Nautilus Biotechnology from 'Neutral' to 'Sell', citing increased competition and product launch delays. Nautilus's instrument launch, originally scheduled for late 2023, is now anticipated for the second half of 2025. The company faces challenges in developing an instrument that offers extensive proteome coverage and high throughput. Nautilus's stock is trading near its 52-week low, with negative EBITDA and a market capitalization of $279 million. Despite challenges, Nautilus aims for a commercial launch of its proteomics products in late 2025.

Nautilus Biotechnology's Parag Mallick, Ph.D., receives the 2024 Distinguished Investigator Award from the Academy for Radiology and Biomedical Imaging Research, recognizing his significant contributions to imaging research.

Nautilus Biotechnology co-founder and Chief Scientist Parag Mallick, Ph.D., received the 2024 Distinguished Investigator Award from the Academy for Radiology and Biomedical Imaging Research, recognizing his significant contributions to imaging research.

Nautilus Biotechnology, Inc. reports beating Q3 2024 earnings expectations with an EPS of $-0.13 versus $-0.17 expected. The company discusses progress in proteomics, including advancements in single molecule intact protein analysis and the addition of Ken Suzuki as Chief Marketing Officer. Nautilus highlights challenges in achieving broad scale proteomics milestones and the potential impact of their platform on biomedical research and drug development. The company remains focused on financial management and anticipates a commercial launch of their broad scale product in late 2025.